^
Association details:
| Biomarker: | TYRO3 mutation + ALK mutation |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor
Published date:
04/19/2021
Excerpt:
...alterations in TYRO3 by FoundationOne, and the discovery of mutations in ALK in the COA109 PDX...there was no significant difference between the tumor growth rate of the control treated group and those treated with crizotinib (Fig. 6A, B). Sunitinib alone significantly delayed COA109 tumor growth (p ≤ 0.001, Fig. 6A, B). Further, the addition of sunitinib to crizotinib diminished tumor growth compared to the control (p ≤ 0.05) and crizotinib treated groups, but not to sunitinib alone.
DOI:
https://doi.org/10.1016/j.tranon.2021.101099
Test:
